GM‐CSF has been demonstrated to increase neutrophil PD‐L1 levels in gastric cancer.[7a] Consistently, GM‐CSF, rather than M‐CSF, was able to upregulate neutrophil surface PD‐L1 expression (Figure 4D). This evidence concerns the gene CSF2 and gastric cancer.